Opioid Use Disorder Treatment Market To Reach $12.82 Billion by 2035

Opioid use disorder treatment market was valued at $4.65 billion in 2025 and is projected to reach $12.82 billion by 2035, growing at a CAGR of 10.66% during the forecast period (2026–2035). The rising global burden of opioid dependence is a key macro driver supporting market growth. According to the World Health Organization (WHO), approximately 39.5 million people worldwide were suffering from drug use disorders, with opioids accounting for a significant share of drug-related deaths globally. The increasing prevalence of opioid misuse across both developed and developing economies is accelerating the demand for effective treatment solutions including pharmacotherapy and behavioural therapy interventions. Governments and healthcare organizations are strengthening addiction treatment programs, improving access to medications such as methadone, buprenorphine, and naltrexone, and expanding rehabilitation infrastructure, thereby supporting sustained market expansion.

Browse the full report description of “Opioid Use Disorder Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Pharmacotherapy, Behavioural Therapy, Combined Treatment), By Drug Type (Partial Opioid Agonists, Full Opioid Agonists, Opioid Antagonists), By End-User (Hospitals, Specialty Addiction Treatment Centers, Rehabilitation Centers, Ambulatory Care Centers, Homecare Settings), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/opioid-use-disorder-market

Increasing Healthcare Interventions Driving Treatment Adoption

The expansion of healthcare interventions and policy frameworks aimed at controlling opioid misuse is significantly influencing market demand. According to the U.S. Food and Drug Administration (FDA), multiple medication-assisted treatment (MAT) products have been approved and promoted to address opioid dependency, improving patient outcomes and reducing relapse rates. Pharmacotherapy remains the most widely adopted treatment approach due to its effectiveness in managing withdrawal symptoms and reducing opioid cravings. Additionally, increasing awareness programs and national strategies to combat opioid addiction are encouraging early diagnosis and treatment adoption across healthcare settings.

Rising Treatment Accessibility Supporting Market Growth

Growing investments in addiction treatment infrastructure and healthcare accessibility are creating strong opportunities for market players. According to the Organisation for Economic Co-operation and Development (OECD), mental health and substance abuse services have seen increased funding across several countries to address rising addiction rates. Specialty addiction treatment centers and rehabilitation facilities are expanding rapidly to accommodate growing patient volumes. Furthermore, the integration of digital health platforms and telemedicine in addiction treatment is enhancing patient monitoring and treatment adherence, thereby strengthening market growth globally.

Key Leaders Transforming the Opioid Use Disorder Treatment Market
The key players in the opioid use disorder treatment market include Indivior PLC, Alkermes plc, Camurus AB, Orexo AB, and Hikma Pharmaceuticals, among others. These companies are focusing on product innovation, long-acting drug formulations, and strategic collaborations to enhance treatment effectiveness and patient compliance.

• In April 2026, Alkermes plc initiated the Brilliance Studies, a Phase 3 clinical program evaluating the safety and efficacy of its investigational oral orexin 2 receptor agonist, alixorexton, for the treatment of narcolepsy type 1 (NT1) and type 2 (NT2). The program includes three randomized, double-blind, placebo-controlled studies assessing once-daily and split-dose regimens, strengthening the company’s clinical pipeline and expanding its central nervous system (CNS) therapeutic portfolio.
• In March 2026, Alkermes plc announced the launch of its inaugural Alkermes Pathways APN Research Awards™ program, a competitive grant initiative aimed at supporting research by psychiatric-mental health nurse practitioners. The program focuses on advancing treatment approaches for schizophrenia and bipolar I disorder, strengthening clinical research capabilities and expanding the company’s engagement in mental health innovation.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Treatment Type
• Drug Type
• End-User
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape – Indivior PLC, Alkermes plc, Camurus AB, Orexo AB, Hikma Pharmaceuticals, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Opioid Use Disorder (OUD) Treatment Market Segmentation

By Treatment Type

• Pharmacotherapy
• Behavioural Therapy
• Combined Treatment

 By Drug Type

• Partial Opioid Agonists
• Full Opioid Agonists
• Opioid Antagonists

By End-User

• Hospitals
• Specialty Addiction Treatment Centers
• Rehabilitation Centers
• Ambulatory Care Centers
• Homecare Settings

Global Opioid Use Disorder Treatment Market Report Segment by Region
North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/opioid-use-disorder-market